metoclopramide and Migraine Disorders studies

Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.

Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Research Excerpts

Excerpt	Relevance	Reference
"To compare the efficacy and frequency of akathisia and dystonia between the dopamine antagonist headache medications olanzapine, metoclopramide and prochlorperazine."	8.31	Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients. ( Brunette, ND; Chinn, E; Cole, JB; DeVries, P; Driver, BE; Klein, LR; Miner, JR; Mojica, E; Raiter, A; Stang, JL, 2023)
"To report a case of sustained hypotension associated with the use of intravenous metoclopramide."	7.79	Sustained hypotension following intravenous metoclopramide. ( Nguyen, TT; Petzel Gimbar, RM, 2013)
" In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine."	7.73	Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005)
" We hypothesized that dexamethasone 16 mg IV would allow greater rates of sustained headache relief than 4 mg when coadministered with metoclopramide 10 mg IV."	5.69	Randomized Trial Comparing Low- vs High-Dose IV Dexamethasone for Patients With Moderate to Severe Migraine. ( Adler, N; Cain, D; Feliciano, C; Friedman, BW; Irizarry, E; Kessler, BD; Lutz, CL; Martorello, K; Moss, H; Solorzano, C, 2023)
"The objective of this study was to assess the efficacy and safety of a common monotherapy (intravenous [iv] metoclopramide) compared to a combination strategy (adding iv ketorolac to metoclopramide) in children presenting for acute treatment of migraine headache in the emergency department (ED)."	5.51	A randomized trial of ketorolac and metoclopramide for migraine in the emergency department. ( Ali, S; Johnson, DW; Newton, AS; Richer, LP; Rosychuk, RJ; Rowe, BH, 2022)
" Compared to other active drugs, it only showed a lower significant effect compared with granisetron regarding headache change while it showed significantly higher effects only with placebo in both rescue medication needs and headache-free symptoms and valproate in only rescue medication need."	5.41	The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. ( Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW, 2023)
"This review was designated to evaluate the efficacy of parenteral ketorolac in treating acute migraine headache."	5.22	Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis. ( Abu Bakar, MA; Baharuddin, KA; Norhayati, MN; Nurathirah, MN; Yazid, MB, 2022)
" Addition of metoclopramide 10 mg improves relief of nausea and vomiting."	4.89	Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; Moore, RA, 2013)
" Addition of metoclopramide 10 mg improves relief of nausea and vomiting."	4.86	Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; McQuay, HJ; Moore, RA, 2010)
"To compare the efficacy and frequency of akathisia and dystonia between the dopamine antagonist headache medications olanzapine, metoclopramide and prochlorperazine."	4.31	Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients. ( Brunette, ND; Chinn, E; Cole, JB; DeVries, P; Driver, BE; Klein, LR; Miner, JR; Mojica, E; Raiter, A; Stang, JL, 2023)
"We report a case of acute dystonia of the face, jaw and tongue caused by metoclopramide and mimicking angioedema."	3.79	Acute dystonia mimicking angioedema of the tongue: a video-illustrated case. ( Bygum, A; Pallesen, KA; Rasmussen, ER, 2013)
"To report a case of sustained hypotension associated with the use of intravenous metoclopramide."	3.79	Sustained hypotension following intravenous metoclopramide. ( Nguyen, TT; Petzel Gimbar, RM, 2013)
" However, long-term use of NSAIDs is associated with side-effects, mainly involving the gastrointestinal tract."	3.77	[Migraine and non-steroidal anti-inflammatory agents]. ( Pradalier, A; Vincent, D, 1992)
" In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine."	3.73	Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005)
"Hypertension and migraines were the most common comorbidities, with a third of the patients reporting an aura."	3.01	MAGraine: Magnesium compared to conventional therapy for treatment of migraines. ( Ahmad, U; Burkins, J; Cirone, M; Desai, D; Jaber, S; Kandil, M; Lomotan, N; McDowell, M; Nuñez Cruz, S, 2021)
"Eligible patients met the migraine criteria of the International Headache Society were randomized to receive 10 mg intravenous metoclopramide, 50 mg intravenous dexketoprofen trometamol, or 50 mg dexketoprofen trometamol +10 mg metoclopramide."	2.94	Intravenous metoclopramide versus dexketoprofen trometamol versus metoclopramide+ dexketoprofen trometamol in acute migraine attack in the emergency department: A randomized double-blind controlled trial. ( Gulacti, U; Lok, U; Turgut, K; Yavuz, E, 2020)
"Patients with migraine of moderate or severe intensity were randomized to receive bilateral GONB with each side administered 3 mL of bupivacaine 0."	2.94	A Randomized, Double-Dummy, Emergency Department-Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine. ( Bijur, PE; Del Valle, M; Friedman, BW; Gallagher, EJ; Harrilal, MA; Irizarry, E; Robbins, MS; Solorzano, C; Williams, A; Zias, E, 2020)
"Sixty acute migraine attack patients were assigned to 3 groups of 20 patients each."	2.87	The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. ( Cevik, Y; Çorbacioglu, ŞK; Dagar, S; Emektar, E; Korucu, O, 2018)
"Patients with acute migraine who reported persistence of a moderate or severe headache for at least 1 hour or longer after treatment with 10 mg of intravenous metoclopramide were randomized to bilateral GONB with a total of 6 mL of 0."	2.87	A Randomized, Sham-Controlled Trial of Bilateral Greater Occipital Nerve Blocks With Bupivacaine for Acute Migraine Patients Refractory to Standard Emergency Department Treatment With Metoclopramide. ( Friedman, BW; Irizarry, E; John Gallagher, E; Mohamed, S; Pearlman, S; Robbins, MS; Tarsia, V, 2018)
"Included patients met the migraine criteria of the International Headache Society."	2.84	Intranasal Lidocaine in Acute Treatment of Migraine: A Randomized Controlled Trial. ( Akalın, LE; Alyeşil, C; Avcu, N; Doğan, NÖ; Pekdemir, M; Yaka, E; Yılmaz, S, 2017)
"Haloperidol has been shown to be effective for migraine treatment."	2.80	A Randomized Controlled Trial of Intravenous Haloperidol vs. Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department. ( Bruner, DI; Frumkin, K; Gaffigan, ME; Pritchard, A; Wason, C, 2015)
"Sixty-four patients of menstrual migraine were randomized into a subgaleal acupoint injection group and a medication group, 32 cases in each one."	2.80	[Preventive effect on menstrual migraine treated with subgaleal acupoint injection with metoclopramide]. ( Su, X; Wang, L; Wu, Y, 2015)
"Rizatriptan was found more efficacious than conventional therapy in terminating an attack of migraine and its' associated symptoms but looking into the contra-indications, side-effects and cost of the former there has been limitation in its prescription as well as the use."	2.79	Clinicopharmacological comparative study of rizatriptan versus conventional therapy in migraine. ( Kushwah, A; Tomar, A, 2014)
"Metoclopramide is a well-known anti-emetic drug with central and peripheral pharmacological effects."	2.76	Metoclopramide as an analgesic in severe migraine attacks: an open, single-blind, parallel control study. ( Cuello, D; Fragoso, M; Salazar, G; Sergio, P; Vergez, L, 2011)
"For patients with migraine, who fail to improve after treatment with a first-line medication, it is reasonable to use an intravenous NSAID or intravenous acetaminophen."	2.72	Second-line interventions for migraine in the emergency department: A narrative review. ( Fakherddine, M; Friedman, BW; Kazi, F; Manyapu, M; Mekuria, K, 2021)
"Migraine is one of the commonest diseases of clinical practice."	2.72	[Comparison of intravenous dipyrone to intravenous metoclopramide in the treatment of acute crisis of migraine: randomized clinical trial]. ( Costa, MS; Fernandes Filho, SM; Fernandes, MT; Foerster, MV, 2006)
"When compared at 2 and 24 hours, aggressive (20 mg dosed up to four times) IV metoclopramide and 6 mg of subcutaneous sumatriptan relieved migraine headache pain comparably."	2.71	A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. ( Bijur, PE; Corbo, J; Esses, D; Friedman, BW; Gallagher, EJ; Lipton, RB; Solorzano, C, 2005)
"1620 patients with migraine, meeting International Headache Society (IHS) criteria were included in the study."	2.71	[Assessment of efficacy of migraine attack treatment with lysine acetylsalicylate and metoclopramide]. ( Kozubski, W; Stepień, A, 2004)
"Acute migraine attacks are often associated with gastrointestinal symptoms ranging from mild nausea to vomiting."	2.71	[Comparison of the effectiveness of lysine acetylsalicylate and metoclopramide combination with ergotamine plus caffeine in the treatment of migraine attacks]. ( Kozubski, W; Stepień, A, 2004)
" The global incidence of adverse events was 45% higher with EC, though not significant (32 vs."	2.69	Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. ( Geraud, G; Gómez, JP; Henry, P; Joffroy, A; Lainez, JM; Le Jeunne, C; Liaño, H; Pradalier, A; Titus i Albareda, F, 1999)
" Five hundred thirty-five adverse effects were reported after the use of 22,697 sachets."	2.69	Safety and efficacy of combined lysine acetylsalicylate and metoclopramide: repeated intakes in migraine attacks. ( Baudesson, G; Chabriat, H; Danchot, J; Joire, JE; Pradalier, A, 1999)
"Zolmitriptan was well tolerated after all treatment regimens."	2.68	The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. ( Layton, G; Peck, RW; Posner, J; Ridout, G; Seaber, EJ, 1997)
"155 patients suffering from migraine, with or without aura were analysed; the main efficacy criteria being the evolution of the headache intensity: disappearance of headache 2 hours after administration or incomplete improvement (severe to moderate headache reduced to slight headache)."	2.68	[Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks]. ( Cajfinger, F; Guérard des Lauriers, A; Lacoste, JP; Peraudeau, P; Pradalier, A; Scheck, F, 1995)
"Aspirin is commonly used to treat migraine attacks, although sumatriptan, a much more expensive treatment, is also effective."	2.68	The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. ( Chazot, G; Henry, P; Mulder, LJ; Scheldewaert, RG; Schoenen, J; Tfelt-Hansen, P, 1995)
"Patients presenting to the ED with migraine requiring parenteral treatment."	2.67	A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. ( Allen, CL; Arthur, DC; McClellan, DS; Olshaker, JS; Tek, DS, 1990)
"The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo."	2.67	Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. ( Bousser, MG; Chabriat, H; Danchot, J; Grippon, P; Joire, JE, 1994)
" We suggest dose-response studies to solve the problem of equipotency of doses, when 2 drugs are compared."	2.66	Methodological aspects of drug trials in migraine. ( Olesen, J; Tfelt-Hansen, P, 1985)
"Metoclopramide was somewhat better than pyridoxine as an additive."	2.65	Tolfenamic acid and caffeine: a useful combination in migraine. ( Gothoni, G; Hakkarainen, H; Parantainen, J; Vapaatalo, H, 1982)
"Aspirin was significantly better than placebo for pain but not quite significant for nausea."	2.65	Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. ( Olesen, J; Tfelt-Hansen, P, 1984)
"Tolfenamic acid is a fenamate which inhibits prostaglandin (PG) biosynthesis and may act as a PG antagonist as well."	2.65	Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. ( Kangasniemi, P; Neuvonen, PJ; Tokola, O; Tokola, RA, 1984)
"Migraine headache is a common disorder; patients attending Emergency Departments (ED) for migraine symptoms internationally account for 1-3% of total ED annual attendances."	2.53	Systematic review: Is Metoclopramide more effective than Sumatriptan in relieving pain from migraine in adults in the Emergency Department (ED) setting? ( Barleycorn, D, 2016)
"Patients with migraine attack need rapid pain relief rather than diagnostic modalities."	2.52	Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis. ( Eken, C, 2015)
"Mild migraine attack can be treated with acetaminophen or NSAIDs either alone or combined with metoclopramide."	2.52	[Update on Current Care Guideline: Migraine]. ( , 2015)
"Migraine is a common, disabling condition and a burden for the individual, health services and society."	2.49	Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Moore, RA, 2013)
"Migraine is a common, disabling condition and a burden for the individual, health services and society."	2.46	Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; McQuay, HJ; Moore, RA, 2010)
"Metoclopramide is an effective treatment for migraine headache and may be effective when combined with other treatments."	2.42	Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. ( Brown, MD; Colman, I; Grafstein, E; Innes, GD; Roberts, TE; Rowe, BH, 2004)
"Nausea and vomiting are common symptoms of migraine, which can be controlled with a variety of anti-emetics including phenothiazines and antihistamines."	2.41	Anti-emetics. ( MacGregor, EA, 2001)
" Successful treatment requires adequate dosing plus choosing the optimal route for drug delivery."	2.40	Management of an acute primary headache. ( Ward, TN, 1998)
"Metoclopramide also has an important place in the investigation of the role of dopamine in physiological and pathological processes."	2.37	Metoclopramide--a review. ( Desmond, PV; Watson, KJ, 1986)
"Most patients had had migraine diagnosed previously (77."	1.72	Migraine in the Emergency Department: A Prospective Multinational Study of Patient Characteristics, Management, and Outcomes. ( Body, R; Chu, KH; Graham, CA; Horner, D; Kamona, S; Karamercan, MA; Keijzers, G; Kelly, AM; Kinnear, FB; Klim, S; Kuan, WS; Laribi, S; Roberts, T; Wijeratne, T, 2022)
"Having these migraine-specific prescriptions may improve self-treatment at home should a migraine attack recur."	1.56	A Brief Look at Urgent Care Visits for Migraine: The Care Received and Ideas to Guide Migraine Care in this Proliferating Medical Setting. ( Miller, L; Minen, MT; Zhou, K, 2020)
"Acetaminophen was the most frequent medicine administered first (53%, 38/72)."	1.51	Migraine Treatment in Pregnant Women Presenting to Acute Care: A Retrospective Observational Study. ( Hamilton, KT; Robbins, MS, 2019)
" Long-term use of various drugs and increased risk of diverse side effects is an unavoidable reality in this population of patients."	1.51	Factors Associated with Insulin Resistance in Women with Migraine: A Cross-Sectional Study. ( Gur-Ozmen, S; Karahan-Ozcan, R, 2019)
"Patients were treated for a migraine headache with a combination of ketorolac and one of the following dopamine antagonists: prochlorperazine, metoclopramide, or promethazine."	1.48	Relative Effectiveness of Dopamine Antagonists for Pediatric Migraine in the Emergency Department. ( Fu, R; Hansen, ML; Laurie, A; Ma, OJ; Meckler, GD; Pacheco, S; Sheridan, DC, 2018)
"Metoclopramide is shown to suppress trigeminovascular activation for the first time, providing an experimental basis for its role in migraine."	1.46	Metoclopramide inhibits trigeminovascular activation:evidence for effective acute attack treatment in migraine. ( Akçali, DT; Bolay, H; Doğanay Aydin, H; Vuralli, D, 2017)
"The majority reported use of antimigraine medications during pregnancy (73."	1.43	Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women. ( Amble, NM; Amundsen, S; Nordeng, H; Poole, AC; Øvrebø, TG, 2016)
"Intravenous migraine therapy reduces PTH pain scores for children presenting within 14 days after mTBI."	1.42	Intravenous migraine therapy in children with posttraumatic headache in the ED. ( Byczkowski, T; Chan, S; Kurowski, B; Timm, N, 2015)
"The majority of children with migraines are successfully discharged from the ED and only 1 in 18 required a revisit within 3 days."	1.42	A comparison of acute treatment regimens for migraine in the emergency department. ( Bachur, RG; Monuteaux, MC; Neuman, MI, 2015)
"Chlorpromazine was included as an option for treatment at our institution during this shortage, although limited data exist on the effectiveness in children."	1.40	Chlorpromazine for the treatment of migraine in a pediatric emergency department. ( Kanis, JM; Timm, NL, 2014)
"Chest pain is an alarming symptom; it justifies many visits to the emergency department (ED)."	1.40	Chest pain a manifestation of migraine. ( Roldan, CJ, 2014)
" Therefore, the proposed method is suitable for the routine control of these ingredients in multicomponent dosage forms."	1.39	Capillary electrophoretic determination of antimigraine formulations containing caffeine, ergotamine, paracetamol and domperidone or metoclopramide. ( Alshehri, MM; Alzoman, NZ; Elshahed, MS; Maher, HM; Olah, IV; Rizk, MS; Sultan, MA, 2013)
"Although many high-quality migraine clinical trials have been performed in the emergency department (ED) setting, almost as many different primary outcome measures have been used, making data aggregation and meta-analysis difficult."	1.36	Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures. ( Bijur, PE; Friedman, BW; Lipton, RB, 2010)
"Treatment patterns in migraine patients with cardiovascular risk factors are largely unknown."	1.35	Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile. ( Egberts, AC; Tijssen, CC; Wammes-van der Heijden, EA, 2009)
"Metoclopramide appears to be an effective initial medical treatment for migraine headaches in the emergency department setting, but its pharmacologic mechanism remains incompletely understood."	1.35	Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache. ( Griffith, JD; Kyriacou, DN; Mycyk, MB, 2008)
"I present a case of migraine-attack-associated sustained hiccup."	1.33	Metoclopramide for migraine-associated hiccup. ( Gupta, VK, 2006)
" Therefore, it is quite possible that both drugs produce adverse immunological effects in vivo in cases of high dosage or obstruction of elimination."	1.31	[Effect of migraine medications on monocyte chemotaxis] . ( Krumholz, W; Menges, T; Ogal, H; Szalay, G, 2000)
"91 patients with migraine were examined in terms of quantitative evaluation of the severity of the attacks."	1.30	[Differentiated therapy of migraine attack]. ( Amelin, AV; Korenko, LA; Skoromets, AA, 1999)
"of caffeine), was retrospectively studied in 63 patients who used it to abort migraine headaches."	1.28	Abortive migraine therapy with oral naproxen sodium plus metoclopramide plus ergotamine tartrate with caffeine. ( Saadah, HA, 1992)
"An open trial was carried out in eight healthy male and female volunteers to examine the bioavailability as well as the main kinetic parameters of Migränerton (metoclopramide and paracetamol; CAS 364-64-5 and CAS 103-90-2, resp)."	1.28	[Pharmacokinetic aspects of a combination of metoclopramide and paracetamol. Results of a human kinetic study and consequences for migraine patients]. ( Becker, A; Berner, G; Leuschner, F; Vögtle-Junkert, U, 1992)
"Ketorolac IM was compared to DHE and metoclopramide IV in migraine patients whose regular abortive medication had failed and who presented to a headache clinic for acute treatment."	1.28	Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. ( Klapper, JA; Stanton, JS, 1991)
"The main treatment of the acute migraine attack remains sleep, sedation, an anti-nauseant and analgesics, and in some patients 1 or 2 mg of ergotamine tartrate."	1.27	Treatment of the acute migraine attack--current status. ( Wilkinson, M, 1983)
"Benefits of migraine therapy include improvements in the patient's overall health and sense of well-being."	1.27	Management of the migraine patient. ( Gunderson, CH, 1986)
"Metoclopramide pretreatment in migraine attacks increased the serum concentration of tolfenamic acid at 1."	1.27	Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. ( Neuvonen, PJ; Tokola, RA, 1984)
" Patients given aspirin with oral metoclopramide tended to obtain better early pain relief than the other two treatment groups, though by one hour from dosage use of injected metoclopramide was also associated with better pain relief."	1.26	Aspirin treatment of migraine attacks: plasma drug level data. ( Eadie, MJ; Heazlewood, V; Ross-Lee, L; Tyrer, JH, 1982)
"The nausea was relieved in 71% of the patients by placebo and bed rest, but metoclopramide was significantly (p = 0."	1.26	A double blind study of metoclopramide in the treatment of migraine attacks. ( Aebelholt-Krabbe, A; Melgaard, B; Olesen, J; Tfelt-Hansen, P; Veilis, B, 1980)
"In an acute migraine clinic, patients were all treated with metoclopramide 10 mg i."	1.26	Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. ( Olesen, J; Tfelt-Hansen, P, 1980)
"A higher percentage of patients with migraine compared with those with tension headache were either symptom-free or had only slight residual headache on leaving."	1.26	Observations on the treatment of an acute attack of migraine. ( Leyton, M; Wilkinson, M; Williams, K, 1978)
"A simple study of migraine was undertaken in an industrial setting to identify facts about the condition of migraine which had previously been unrecorded in industry."	1.26	Study of migraine and the treatment of acute attacks in industry. ( Harrop, C; Jones, A, 1980)

Research

Studies (166)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Duration of Headache Free Period at 7 Days

Number of Participants With Development of Hypertensive Disease of Pregnancy Within 28 Days

Number of Participants With Development of Hypertensive Disease of Pregnancy Within 7 Days

Number of Participants With Injection Site Complication (Infection, Hematoma, and Ecchymosis)

Number of Participants With Need for Admission for Treatment of Headache

Number of Participants With Need for Crossover Treatment

Number of Participants With Need for Neurology Consult

Number of Participants With Need for Representation for Treatment of Headache With 28 Days

Timeframe	Studies, this research(%)	All Research%
pre-1990	41 (24.70)	18.7374
1990's	32 (19.28)	18.2507
2000's	29 (17.47)	29.6817
2010's	49 (29.52)	24.3611
2020's	15 (9.04)	2.80

Authors	Studies
Kazi, F	1
Manyapu, M	1
Fakherddine, M	1
Mekuria, K	1
Friedman, BW	11
Wijeratne, T	1
Kuan, WS	1
Kelly, AM	2
Chu, KH	1
Kinnear, FB	1
Keijzers, G	1
Body, R	1
Karamercan, MA	1
Klim, S	1
Kamona, S	1
Graham, CA	1
Roberts, T	1
Horner, D	1
Laribi, S	1
Atif, H	1
McGhee, J	1
Nurathirah, MN	1
Yazid, MB	1
Norhayati, MN	1
Baharuddin, KA	1
Abu Bakar, MA	1
Richer, LP	1
Ali, S	1
Johnson, DW	1
Rosychuk, RJ	1
Newton, AS	1
Rowe, BH	2
Chinn, E	1
Brunette, ND	1
Driver, BE	1
Klein, LR	1
Stang, JL	1
DeVries, P	1
Mojica, E	1
Raiter, A	1
Miner, JR	1
Cole, JB	1
Abdelmonem, H	1
Abdelhay, HM	1
Abdelwadoud, GT	1
Alhosini, ANM	1
Ahmed, AE	1
Mohamed, SW	1
Al-Dardery, NM	1
Abd-ElGawad, M	1
Kamel, MA	1
Solorzano, C	6
Kessler, BD	1
Martorello, K	1
Lutz, CL	1
Feliciano, C	1
Adler, N	1
Moss, H	1
Cain, D	1
Irizarry, E	3
Jiang, C	1
Wang, T	1
Qiu, ZG	1
Chen, B	1
Fang, BJ	1
Dolgorukova, A	1
Osipchuk, AV	1
Murzina, AA	1
Sokolov, AY	1
Minen, MT	1
Zhou, K	1
Miller, L	1
Yavuz, E	1
Gulacti, U	1
Lok, U	1
Turgut, K	1
Williams, A	1
Zias, E	1
Robbins, MS	3
Harrilal, MA	1
Del Valle, M	1
Bijur, PE	6
Gallagher, EJ	9
Kandil, M	1
Jaber, S	1
Desai, D	1
Nuñez Cruz, S	1
Lomotan, N	1
Ahmad, U	1
Cirone, M	1
Burkins, J	1
McDowell, M	1
Oswald, JC	1
Schuster, NM	1
Wells, S	1
Stiell, IG	1
Vishnyakova, E	1
Lun, R	1
Nemnom, MJ	1
Perry, JJ	1
Korucu, O	1
Dagar, S	1
Çorbacioglu, ŞK	1
Emektar, E	1
Cevik, Y	1
Mohamed, S	1
Tarsia, V	1
Pearlman, S	1
John Gallagher, E	1
Hamilton, KT	1
Smith, JH	1
Potter, JL	1
Robblee, JV	1
Doğan, NÖ	2
Pekdemir, M	2
Yılmaz, S	2
Yaka, E	2
Karadaş, A	1
Durmuş, U	1
Avcu, N	2
Koçkan, E	1
Khazaei, M	1
Hosseini Nejad Mir, N	1
Yadranji Aghdam, F	1
Taheri, M	1
Ghafouri-Fard, S	1
Gur-Ozmen, S	1
Karahan-Ozcan, R	1
Derry, S	5
Moore, RA	5
Kirthi, V	3
Rasmussen, ER	1
Pallesen, KA	1
Bygum, A	1
Choi, H	1
Parmar, N	1
Roldan, CJ	1
Nguyen, TT	1
Petzel Gimbar, RM	1
Kanis, JM	1
Timm, NL	1
Garber, L	3
Yoon, A	1
Wollowitz, A	1
Esses, D	5
Ingledue, VF	1
Mounsey, A	1
Saguil, A	1
Lax, JW	1
Shahrami, A	1
Assarzadegan, F	1
Hatamabadi, HR	1
Asgarzadeh, M	1
Sarehbandi, B	1
Asgarzadeh, S	1
Factor, SA	1
Jankovic, J	2
Eken, C	1
Bachur, RG	1
Monuteaux, MC	1
Neuman, MI	1
Chan, S	1
Kurowski, B	1
Byczkowski, T	1
Timm, N	1
Kushwah, A	1
Tomar, A	1
Gaffigan, ME	1
Bruner, DI	1
Wason, C	1
Pritchard, A	1
Frumkin, K	1
Wang, L	1
Wu, Y	1
Su, X	1
Cabral, L	1
Adewunmi, V	1
Kaar, CR	1
Gerard, JM	1
Nakanishi, AK	1
Wijemanne, S	1
Evans, RW	1
Barleycorn, D	1
Sheridan, DC	1
Laurie, A	1
Pacheco, S	1
Fu, R	1
Hansen, ML	1
Ma, OJ	1
Meckler, GD	1
Gulseren, D	1
Sahin, EB	1
Bozdogan, O	1
Artuz, F	1
Amundsen, S	1
Øvrebø, TG	1
Amble, NM	1
Poole, AC	1
Nordeng, H	1
Davenport, WJ	1
Pringsheim, TM	1
Fisher, H	1
Alyeşil, C	1
Akalın, LE	1
Doğanay Aydin, H	1
Vuralli, D	1
Akçali, DT	1
Bolay, H	1
Friedman, B	1
Bijur, P	2
Greenwald, P	2
Lipton, R	1
Wammes-van der Heijden, EA	1
Tijssen, CC	1
Egberts, AC	1
Walcynski, T	1
Gunn, B	1
Lipton, RB	3
McQuay, HJ	2
DeDea, L	1
Salazar, G	1
Fragoso, M	1
Vergez, L	1
Sergio, P	1
Cuello, D	1
Wainscott, G	1
Kaspi, T	1
Volans, GN	2
McQuay, H	1
Gelfand, AA	1
Goadsby, PJ	1
Sultan, MA	1
Maher, HM	1
Alzoman, NZ	1
Alshehri, MM	1
Rizk, MS	1
Elshahed, MS	1
Olah, IV	1
Gupta, R	1
Gupta, S	1
Wyderski, RJ	1
MacGregor, EA	1
Fox, AW	1
Stepień, A	2
Kozubski, W	2
Colman, I	1
Brown, MD	1
Innes, GD	1
Grafstein, E	1
Roberts, TE	1
Pradalier, A	4
Chabriat, H	2
Danchot, J	2
Baudesson, G	1
Joire, JE	2
Swidan, SZ	1
Lake, AE	1
Saper, JR	1
Cheng, FH	1
Andrews, PL	1
Moreaux, B	1
Ngan, MP	1
Rudd, JA	1
Sam, TS	1
Wai, MK	1
Wan, C	1
Cete, Y	1
Dora, B	1
Ertan, C	1
Ozdemir, C	1
Oktay, C	1
Corbo, J	2
Brenner, SR	1
Allena, M	1
Magis, D	1
Schoenen, J	3
Gupta, VK	1
Hakkarainen, H	2
Allonen, H	1
Fernandes Filho, SM	1
Costa, MS	1
Fernandes, MT	1
Foerster, MV	1
Griffith, JD	1
Mycyk, MB	1
Kyriacou, DN	1
Dua, N	1
Radulescu, R	1
Chang, E	1
Hochberg, M	1
Campbell, C	1
Aghera, A	1
Valentin, T	1
Paternoster, J	1
Azzopardi, TD	1
Brooks, NA	1
Tfelt-Hansen, P	8
Olesen, J	7
Tokola, RA	3
Kangasniemi, P	1
Neuvonen, PJ	2
Tokola, O	1
Wilkinson, M	3
Peatfield, R	1
Damasio, H	1
Jensen, K	1
Vendsborg, P	1
Lauritzen, M	1
Blau, JN	1
Ross-Lee, LM	1
Eadie, MJ	2
Heazlewood, V	2
Bochner, F	1
Tyrer, JH	2
Parantainen, J	1
Gothoni, G	1
Vapaatalo, H	1
Lewis, RH	1
Fozard, JR	1
Ross-Lee, L	1
Behan, P	1
Giacovazzo, M	1
Aebelholt-Krabbe, A	1
Melgaard, B	1
Veilis, B	3
Jones, A	1
Harrop, C	1
Coppola, M	1
Yealy, DM	1
Leibold, RA	1
Henry, P	4
Mulder, LJ	2
Scheldewaert, RG	2
Chazot, G	2
Scherl, ER	1
Wilson, JF	1
Hiesse-Provost, O	1
Dillenschneider, A	1
Ganry, H	1
Insuasty, J	1
Grippon, P	1
Bousser, MG	1
Anaya Ordóñez, S	1
Matas Hoces, A	1
Kumar, KL	1
Ellis, GL	1
Delaney, J	1
DeHart, DA	1
Owens, A	1
Cameron, JD	1
Lane, PL	1
Speechley, M	1
Graf, WD	1
Riback, PS	1
MacCumber, MW	1
Jaffe, GJ	1
McCuen, BW	1
Ducharme, J	1
Beveridge, R	1
Jones, J	1
Pack, S	1
Chun, E	1
Chrubasik, S	1
Chrubasik, J	1
Torrance, C	1
Jordan, S	1
Guérard des Lauriers, A	1
Scheck, F	1
Peraudeau, P	1
Lacoste, JP	1
Cajfinger, F	1
Seaber, EJ	1
Ridout, G	1
Layton, G	1
Posner, J	1
Peck, RW	1
Ward, TN	1
Le Jeunne, C	1
Gómez, JP	1
Titus i Albareda, F	1
Joffroy, A	1
Liaño, H	2
Lainez, JM	1
Geraud, G	2
Skoromets, AA	1
Amelin, AV	1
Korenko, LA	1
Krumholz, W	1
Szalay, G	1
Ogal, H	1
Menges, T	1
McGinnis, J	1
Seaton, TL	1
Iannaccone, R	1
Compagnon, A	1
Rossi, A	1
Aebelholt, A	1
Milton-Thompson, GJ	1
Krabbe, AA	1
Hughes, JB	1
Williams, K	1
Leyton, M	1
Naess, K	1
Houghton, LA	1
Fowler, P	1
Keene, ON	1
Read, NW	1
Eldor, J	1
Schwartzberg, M	1
Vincent, D	1
Saadah, HA	1
Becker, A	1
Berner, G	1
Leuschner, F	1
Vögtle-Junkert, U	1
Klapper, JA	1
Stanton, JS	1
Tek, DS	1
McClellan, DS	1
Olshaker, JS	1
Allen, CL	1
Arthur, DC	1
Burke, M	1
Kunkel, RS	1
Richter, R	1
Desmond, PV	1
Watson, KJ	1
Shaughnessy, AF	1
Dexter, SL	1
Graham, AN	1
Johnston, ES	1
Ratcliffe, DM	1
Wilkinson, MI	1
Rose, AJ	1
Gunderson, CH	1
Girard, D	1
Turner, P	1
Matts, SG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Impact of Virtual Reality -Guided Visual and Auditory Therapy on Symptom Severity and Psychological Well-Being in Tension-Type Headache Patients: A Controlled Study[NCT06155669]		100 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches: Randomized Observational Study[NCT06061588]		100 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial[NCT04252521]		150 participants (Actual)	Interventional	2019-07-03	Completed
Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial[NCT03951649]	Phase 4	62 participants (Actual)	Interventional	2020-02-10	Completed
A Randomized Double-blind Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache[NCT03472872]	Phase 4	500 participants (Actual)	Interventional	2017-09-05	Terminated (stopped due to no longer recruiting or studying)
IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine[NCT02664116]	Phase 4	40 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Effect of Intravenous Infusion of Magnesium Sulfate Associated or Not to Lidocaine On the Neuromuscular Blockade Induced by Muscle Relaxant Cistracurium[NCT02483611]	Phase 4	48 participants (Actual)	Interventional	2015-07-31	Completed
Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial.[NCT01825941]	Phase 4	208 participants (Actual)	Interventional	2013-04-30	Completed
Sphenopalatine Ganglion Blocks for Headaches in the Emergency Department[NCT04255420]	Phase 4	84 participants (Anticipated)	Interventional	2020-02-21	Recruiting
Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326]		300 participants (Anticipated)	Interventional	2012-03-01	Completed
The Utility of Adding 1 L Intravenous Normal Saline to Standard 75 mg Intramuscular Diclofenac Potassium Injection in Patients Presented to the Emergency Department With an Acute Migraine Attack[NCT04287140]		120 participants (Anticipated)	Interventional	2020-04-01	Recruiting
The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.[NCT02657031]	Phase 4	54 participants (Actual)	Interventional	2016-03-17	Completed
Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial[NCT03185130]	Phase 4	58 participants (Actual)	Interventional	2017-05-16	Completed
Oral v. Parenteral Medications for the Emergency Management of Acute Migraine: a Pilot Randomized Control Trial[NCT05983354]		55 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Randomized Double Blinded Study Comparing Use of Prochlorperazine Versus Prochlorperazine and Ketorolac in the Treatment of Pediatric Migraine in the Emergency Department[NCT01534806]	Phase 4	0 participants (Actual)	Interventional	2012-01-31	Withdrawn (stopped due to Drug is backordered;)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	days (Median)
Occipital Nerve Block	6
Oral Acetaminophen/Caffeine Group	1

Intervention	Participants (Count of Participants)
Occipital Nerve Block	9
Oral Acetaminophen/Caffeine Group	4

Intervention	Participants (Count of Participants)
Occipital Nerve Block	7
Oral Acetaminophen/Caffeine Group	2

Intervention	Participants (Count of Participants)
Occipital Nerve Block	0
Oral Acetaminophen/Caffeine Group	2

Intervention	Participants (Count of Participants)
Occipital Nerve Block	0
Oral Acetaminophen/Caffeine Group	0

Intervention	Participants (Count of Participants)
Occipital Nerve Block	9
Oral Acetaminophen/Caffeine Group	14

Intervention	Participants (Count of Participants)
Occipital Nerve Block	4
Oral Acetaminophen/Caffeine Group	2

Emergency department for treatment of headache since treatment asked at 28 day follow up (NCT03951649)
Timeframe: 28 days

Number of Participants With Need for Second Line Treatment

Number of Participants With Response to Occipital Nerve Block in Pregnancy

Intervention	Participants (Count of Participants)
Occipital Nerve Block	5
Oral Acetaminophen/Caffeine Group	1

Intervention	Participants (Count of Participants)
Occipital Nerve Block	5
Oral Acetaminophen/Caffeine Group	5

Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail. (NCT03951649)
Timeframe: 60-300 min

Response to Cross Over Treatment at 60 Min

Intervention	Participants (Count of Participants)
Occipital Nerve Block	20
Oral Acetaminophen/Caffeine Group	16

"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 60 min

Response to Second Line Treatment at 60 Min

Intervention	score on a scale (Median)
Occipital Nerve Block	6
Oral Acetaminophen/Caffeine Group	3

Response to Treatment Within 2 Hours

Intervention	score on a scale (Median)
Occipital Nerve Block	6
Oral Acetaminophen/Caffeine Group	4

Clinical Duration

Intervention	score on a scale (Median)
Occipital Nerve Block	6.0
Oral Acetaminophen/Caffeine Group	6.5

"The clinical duration is the elapsed time for T1 recovery = 25% (Dur25%) of the original value of T1 after the infusion of cisatracurium.~This outcome meansure was presented in minutes." (NCT02483611)
Timeframe: Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes

Final Recovery Index

Intervention	minutes (Median)
Group M	82.68
Group ML	86.33
Group C	64.8

"The final recovery index is the elapsed time between the T1 recovery = 25% (Dur25%) and T4 / T1 = 80% (TOF = 80%) after the infusion of cisatracurium.~This outcome measure was presented in minutes." (NCT02483611)
Timeframe: Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes

HR - M1 (Heart Rate in the Moment 1)

Intervention	minutes (Mean)
Group M	27.97
Group ML	33.81
Group C	21.51

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The measure of heart rate was recorded and annotated at various times such as in the arrival of the patient in the operating room. This time point was named as moment '1'. (NCT02483611)
Timeframe: This measure of heart rate was performed when the patient arrived in the operating room

HR - M2 (Heart Rate in the Moment 2)

Intervention	beats/min (Mean)
Group M	79.94
Group ML	77.25
Group C	73.66

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as in the moment immediately before the anesthesia induction. This time point was named as moment '2'. (NCT02483611)
Timeframe: This measure of heart rate was performed immediately before induction of anesthesia

HR - M3 (Heart Rate in the Moment 3)

Intervention	beats/min (Mean)
Group M	74.69
Group ML	73.69
Group C	75.40

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution). This time point was named as moment '3'. (NCT02483611)
Timeframe: This measure of heart rate was performed immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution)

HR - M4 (Heart Rate in the Moment 4)

Intervention	beats/min (Mean)
Group M	72.94
Group ML	74.19
Group C	75.40

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as in the end of the study solutions infusion. This time point was named as moment '4'. (NCT02483611)
Timeframe: This measure of heart rate was performed five minutes after M3 (in the end of the X and Y solutions infusion)

HR - M5 (Heart Rate in the Moment 5)

Intervention	beats/min (Mean)
Group M	71.94
Group ML	72.25
Group C	65.07

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as immediately before the tracheal intubation. This time point was named as moment '5'. (NCT02483611)
Timeframe: This measure of heart rate was performed immediately before the tracheal intubation

HR - M6 (Heart Rate in the Moment 6)

Intervention	beats/min (Mean)
Group M	67.56
Group ML	69.31
Group C	64.27

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as one minute after the tracheal intubation. This time point was named as moment '6'. (NCT02483611)
Timeframe: This measure of heart rate was performed one minute after the tracheal intubation

HR - M7a (Heart Rate in the Moment 7a)

Intervention	beats/min (Mean)
Group M	66.50
Group ML	68.19
Group C	65.13

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 15 minutes after the traqueal intubation.This time point was named as moment '7a'. (NCT02483611)
Timeframe: This measure of heart rate was performed 15 minutes after the traqueal intubation

HR - M7b (Heart Rate in the Moment 7b)

Intervention	beats/min (Mean)
Group M	68.94
Group ML	68.19
Group C	67.13

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 30 minutes after the traqueal intubation. This time point was named as moment '7b'. (NCT02483611)
Timeframe: This measure of heart rate was performed 30 minutes after the traqueal intubation

HR - M7c (Heart Rate in the Moment 7c)

Intervention	beats/min (Mean)
Group M	67.44
Group ML	68.38
Group C	64.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 45 minutes after the traqueal intubation. This time point was named as moment '7c'. (NCT02483611)
Timeframe: This measure of heart rate was performed 45 minutes after the traqueal intubation

HR - M7d (Heart Rate in the Moment 7d)

Intervention	beats/min (Mean)
Group M	65.75
Group ML	65.75
Group C	62.33

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 60 minutes after the traqueal intubation. This time point was named as moment '7d'. (NCT02483611)
Timeframe: This measure of heart rate was performed 60 minutes after the traqueal intubation

HR - M7e (Heart Rate in the Moment 7e)

Intervention	beats/min (Mean)
Group M	66.19
Group ML	65.31
Group C	61.93

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 75 minutes after the traqueal intubation. This time point was named as moment '7e'. (NCT02483611)
Timeframe: This measure of heart rate was performed 75 minutes after the traqueal intubation

HR - M7f (Heart Rate in the Moment 7f)

Intervention	beats/min (Median)
Group M	66.50
Group ML	63.00
Group C	58.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 90 minutes after the traqueal intubation. This time point was named as moment '7f'. (NCT02483611)
Timeframe: This measure of heart rate was performed 90 minutes after the traqueal intubation

Latency

Intervention	beats/min (Median)
Group M	66.00
Group ML	61.00
Group C	61.00

"The latency is computed as the elapsed time to reduce the response of T1 to 5% of the initial contraction force after the infusion of cisatracurium.~This outcome meansure was presented in seconds." (NCT02483611)
Timeframe: Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes

MAP - M1 (Mean Arterial Pressure in the Moment 1)

Intervention	seconds (Mean)
Group M	139.70
Group ML	151.30
Group C	147.80

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as in the arrival of the patient in the operating room. This time point was named as moment '1'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed when the patient arrived in the operating room

MAP - M2 (Mean Arterial Pressure in the Moment 2)

Intervention	mmHg (Mean)
Group M	94.63
Group ML	88.75
Group C	100.10

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as in the moment immediately before the anesthesia induction. This time point was named as moment '2'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed immediately before induction of anesthesia

MAP - M3 (Mean Arterial Pressure in the Moment 3)

Intervention	mmHg (Mean)
Group M	87.63
Group ML	84.69
Group C	92.47

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution). This time point was named as moment '3'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution)

MAP - M4 (Mean Arterial Pressure in the Moment 4)

Intervention	mmHg (Mean)
Group M	75.88
Group ML	73.88
Group C	76.73

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as in the end of the study solutions infusion.This time point was named as moment '4'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed five minutes after M3 (in the end of the X and Y solutions infusion)

MAP - M5 (Mean Arterial Pressure in the Moment 5)

Intervention	mmHg (Median)
Group M	69.00
Group ML	63.00
Group C	74.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as immediately before the tracheal intubation. This time point was named as moment '5'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed immediately before the tracheal intubation

MAP - M6 (Mean Arterial Pressure in the Moment 6)

Intervention	mmHg (Median)
Group M	62.50
Group ML	61.50
Group C	67.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as one minute after the tracheal intubation. This time point was named as moment '6'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed one minute after the tracheal intubation

MAP - M7a (Mean Arterial Pressure in the Moment 7a)

Intervention	mmHg (Median)
Group M	64.50
Group ML	64.00
Group C	69.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 15 minutes after the traqueal intubation. This time point was named as moment '7a'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed 15 minutes after the traqueal intubation

MAP - M7b (Mean Arterial Pressure in the Moment 7b)

Intervention	mmHg (Median)
Group M	66.00
Group ML	61.50
Group C	69.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 30 minutes after the traqueal intubation. This time point was named as moment '7b'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed 30 minutes after the traqueal intubation

MAP - M7c (Mean Arterial Pressure in the Moment 7c)

Intervention	mmHg (Median)
Group M	66.50
Group ML	63.50
Group C	68.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 45 minutes after the traqueal intubation. This time point was named as moment '7c'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed 45 minutes after the traqueal intubation

MAP - M7d (Mean Arterial Pressure in the Moment 7d)

Intervention	mmHg (Mean)
Group M	69.25
Group ML	63.00
Group C	69.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 60 minutes after the traqueal intubation. This time point was named as moment '7d'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed 60 minutes after the traqueal intubation

MAP - M7e (Mean Arterial Pressure in the Moment 7e)

Intervention	mmHg (Median)
Group M	68.00
Group ML	62.00
Group C	66.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 75 minutes after the traqueal intubation. This time point was named as moment '7e'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed 75 minutes after the traqueal intubation

MAP - M7f (Mean Arterial Pressure in the Moment 7f)

Intervention	mmHg (Median)
Group M	68.00
Group ML	66.00
Group C	69.00

In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 90 minutes after the traqueal intubation. This time point was named as moment '7f'. (NCT02483611)
Timeframe: This measure of average blood pressure was performed 90 minutes after the traqueal intubation

Recovery Index

Intervention	mmHg (Median)
Group M	64.00
Group ML	64.50
Group C	72.00

"The recovery index is the elapsed time between the T1 recovery =25% (Dur25%) and T1 =75% (Dur75%) after the infusion of cisatracurium.~This outcome meansure was presented in minutes." (NCT02483611)
Timeframe: Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes

Spontaneous Recovery (T4/T1=90%)

Intervention	minutes (Mean)
Group M	20.08
Group ML	20.26
Group C	14.53

"Spontaneous recovery is the elapsed time for the recovery of the TOF (T4 / T1) response to 90% of the original after infusion of cisatracurium.~This outcome measure was presented in minutes." (NCT02483611)
Timeframe: The participants were followed during the anesthetic - surgical procedure

Total Duration (Dur95%)

Intervention	minutes (Mean)
Group M	120.20
Group ML	126.70
Group C	90.03

"The total duration is the elapsed time for T1 recovery of the response to reach 95% of the initial after the infusion of cisatracurium.~This outcome measure was presented in minutes." (NCT02483611)
Timeframe: Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes

Number of Participants With Sustained Headache Relief Assessed by Self-evaluation

Intervention	minutes (Mean)
Group M	113.20
Group ML	120.10
Group C	88.19

"Sustained headache relief is defined as achieving a headache level of mild or none within two hours and maintaining a level of mild or none for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after discharge from emergency department" (NCT01825941)
Timeframe: up to 2 hours in Emergency Department, 48 hours after discharge from Emergency Department

Anxiety

Intervention	Participants (Count of Participants)
Metoclopramide + Diphenhydramine	40
Metoclopramide + Placebo	38

Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes

Headache Following Intervention

Intervention	mm (Mean)
Control Arm	33.7
Study Arm	21.2

Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes

Nausea

Intervention	mm (Mean)
Control Arm	63.5
Study Arm	43.5

Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes

Article	Year
Second-line interventions for migraine in the emergency department: A narrative review. Headache, 2021, Volume: 61, Issue:10 Topics: Acetaminophen; Administration, Intravenous; Anti-Inflammatory Agents, Non-Steroidal; Emergency Servi	2021
Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2022, Volume: 29, Issue:9 Topics: Caffeine; Dexamethasone; Diclofenac; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Pain; Ph	2022
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. BMC neurology, 2023, Jun-08, Volume: 23, Issue:1 Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea	2023
Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. The Cochrane database of systematic reviews, 2013, Apr-30, Issue:4 Topics: Acetaminophen; Acute Disease; Adult; Analgesics, Non-Narcotic; Antiemetics; Drug Therapy, Combinatio	2013
Aspirin with or without an antiemetic for acute migraine headaches in adults. The Cochrane database of systematic reviews, 2013, Apr-30, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum	2013
BET 1: Metoclopramide or prochlorperazine for headache in acute migraine? Emergency medicine journal : EMJ, 2013, Volume: 30, Issue:7 Topics: Acute Disease; Adult; Benchmarking; Emergency Service, Hospital; Evidence-Based Medicine; Humans; Me	2013
The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. European journal of emergency medicine : official journal of the European Society for Emergency Medicine, 2014, Volume: 21, Issue:1 Topics: Acute Disease; Adult; Dopamine Antagonists; Double-Blind Method; Humans; Magnesium Sulfate; Metoclop	2014
Acute migraine treatment in emergency settings. American family physician, 2014, May-01, Volume: 89, Issue:9 Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Dexamethasone;	2014
Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis. The American journal of emergency medicine, 2015, Volume: 33, Issue:3 Topics: Administration, Intravenous; Antiemetics; Emergency Service, Hospital; Humans; Metoclopramide; Migra	2015
[Update on Current Care Guideline: Migraine]. Duodecim; laaketieteellinen aikakauskirja, 2015, Volume: 131, Issue:19 Topics: Acetaminophen; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opi	2015
Systematic review: Is Metoclopramide more effective than Sumatriptan in relieving pain from migraine in adults in the Emergency Department (ED) setting? International emergency nursing, 2016, Volume: 27 Topics: Adult; Analgesics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Migraine Disor	2016
The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis. Headache, 2009, Volume: 49, Issue:9 Topics: Acute Disease; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Migraine Diso	2009
Aspirin with or without an antiemetic for acute migraine headaches in adults. The Cochrane database of systematic reviews, 2010, Apr-14, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum	2010
Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. The Cochrane database of systematic reviews, 2010, Nov-10, Issue:11 Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Drug Therapy, Combination; Humans; Hype	2010
Aspirin for acute migraine headaches in adults. Journal of neurology, neurosurgery, and psychiatry, 2013, Volume: 84, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Dopamine Antagonists; Drug Therapy, C	2013
Treatment of pediatric migraine in the emergency room. Pediatric neurology, 2012, Volume: 47, Issue:4 Topics: Adolescent; Age Distribution; Age of Onset; Analgesics; Antiemetics; Child; Child, Preschool; Dihydr	2012
Anti-emetics. Current medical research and opinion, 2001, Volume: 17 Suppl 1 Topics: Antiemetics; Domperidone; Dopamine Antagonists; Humans; Metoclopramide; Migraine Disorders; Nausea;	2001
MT 100. Drugs in R&D, 2003, Volume: 4, Issue:1 Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Drug Combinations; Drugs, Investigational;	2003
Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ (Clinical research ed.), 2004, Dec-11, Volume: 329, Issue:7479 Topics: Adult; Antiemetics; Humans; Infusions, Parenteral; Metoclopramide; Migraine Disorders; Randomized Co	2004
Naproxen sodium/metoclopramide: metoclopramide/naproxen-sodium, MT 100, naproxen-sodium/metoclopramide. Drugs in R&D, 2006, Volume: 7, Issue:4 Topics: Animals; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Combinations; Drug Evaluatio	2006
Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:3 Topics: Acute Disease; Administration, Oral; Ambulatory Care; Analgesics; Drug Synergism; Drug Therapy, Comb	2008
Basic mechanisms of antimigraine drugs. Advances in neurology, 1982, Volume: 33 Topics: Amitriptyline; Animals; Chlorpromazine; Humans; Methysergide; Metoclopramide; Migraine Disorders; Pr	1982
Recent advances in the acute management of migraine and cluster headaches. Journal of general internal medicine, 1994, Volume: 9, Issue:6 Topics: Analgesics; Butorphanol; Capsaicin; Cluster Headache; Dihydroergotamine; Humans; Ketorolac; Metoclop	1994
Pharmacologic treatment of recurrent pediatric headache. Pediatric annals, 1995, Volume: 24, Issue:9 Topics: Acetaminophen; Adolescent; Adrenal Cortex Hormones; Analgesics; Aspirin; Child; Child, Preschool; Er	1995
Management of an acute primary headache. Clinical neuroscience (New York, N.Y.), 1998, Volume: 5, Issue:1 Topics: Acute Disease; Cluster Headache; Dose-Response Relationship, Drug; Drug Administration Routes; Heada	1998
The effectiveness of combined oral lysine acetylsalicylate and metoclopramide (Migpriv) in the treatment of migraine attacks. Comparison with placebo and oral sumatriptan. Functional neurology, 2000, Volume: 15 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dopamine Antagonists; Drug Combinations; Humans; L	2000
[Current treatment of migraine]. Revista clinica espanola, 1992, Volume: 191, Issue:3 Topics: Adult; Child; Dihydroergotamine; Ergotamine; Female; Humans; Indoles; Male; Methysergide; Metoclopra	1992
[Migraine and non-steroidal anti-inflammatory agents]. Pathologie-biologie, 1992, Volume: 40, Issue:4 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Ergotamine; Flufenamic	1992
Pharmacologic management of migraine--1985. Cleveland Clinic quarterly, 1985,Spring, Volume: 52, Issue:1 Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Calcium Channel Bloc	1985
[Pharmacotherapy of migraine--indications and experiences]. Zeitschrift fur arztliche Fortbildung, 1988, Volume: 82, Issue:24 Topics: Aspirin; Drug Therapy, Combination; Ergotamine; Humans; Metoclopramide; Migraine Disorders	1988
Metoclopramide--a review. The Medical journal of Australia, 1986, Mar-31, Volume: 144, Issue:7 Topics: Anxiety; Digestive System; Dopamine Antagonists; Drug Interactions; Female; Gastric Emptying; Gastro	1986
Potential uses for metoclopramide. Drug intelligence & clinical pharmacy, 1985, Volume: 19, Issue:10 Topics: Anorexia Nervosa; Bezoars; Dyskinesia, Drug-Induced; Failure to Thrive; Hiccup; Humans; Metocloprami	1985

Article	Year
Migraine in the Emergency Department: A Prospective Multinational Study of Patient Characteristics, Management, and Outcomes. Neuroepidemiology, 2022, Volume: 56, Issue:1 Topics: Adult; Emergency Service, Hospital; Female; Humans; Metoclopramide; Migraine Disorders; Prochlorpera	2022
Randomized IV metoclopramide vs IV ketorolac in treatment of acute primary headache. The American journal of emergency medicine, 2022, Volume: 57 Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Headache; Humans; Ketorola	2022
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients. The American journal of emergency medicine, 2023, Volume: 65 Topics: Cohort Studies; Double-Blind Method; Dystonia; Emergency Service, Hospital; Headache; Humans; Metocl	2023
Efficacy of metoclopramide for the treatment of acute migraine. Medicine, 2019, Volume: 98, Issue:37 Topics: Analgesics; Humans; Meta-Analysis as Topic; Metoclopramide; Migraine Disorders; Randomized Controlle	2019
The Influence of Metoclopramide on Trigeminovascular Nociception: Possible Anti-migraine Mechanism of Action. Neuroscience, 2020, 01-15, Volume: 425 Topics: Action Potentials; Animals; Male; Metoclopramide; Migraine Disorders; Neurons; Nociception; Rats; Ra	2020
A Brief Look at Urgent Care Visits for Migraine: The Care Received and Ideas to Guide Migraine Care in this Proliferating Medical Setting. Headache, 2020, Volume: 60, Issue:3 Topics: Academic Medical Centers; Adolescent; Adult; Antiemetics; Drug Prescriptions; Emergency Service, Hos	2020
A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment. Headache, 2021, Volume: 61, Issue:1 Topics: Anesthetics, Local; Bupivacaine; Emergency Service, Hospital; Humans; Metoclopramide; Migraine Disor	2021
Optimal management strategies for primary headache in the emergency department. CJEM, 2021, Volume: 23, Issue:6 Topics: Adult; Emergency Service, Hospital; Female; Headache; Humans; Ketorolac; Metoclopramide; Migraine Di	2021
Migraine Treatment in Pregnant Women Presenting to Acute Care: A Retrospective Observational Study. Headache, 2019, Volume: 59, Issue:2 Topics: Acetaminophen; Adult; Analgesics; Antiemetics; Diphenhydramine; Drug Therapy, Combination; Female; H	2019
What Is the Optimal Placebo for Clinical Trials of Nerve Blocks in Headache?: An N-of-1 Study of Lactated Ringer's. Headache, 2019, Volume: 59, Issue:1 Topics: Bupivacaine; Emergency Service, Hospital; Headache; Humans; Metoclopramide; Migraine Disorders; Nerv	2019
Factors Associated with Insulin Resistance in Women with Migraine: A Cross-Sectional Study. Pain medicine (Malden, Mass.), 2019, 10-01, Volume: 20, Issue:10 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure; Body Composition; Bod	2019
Acute dystonia mimicking angioedema of the tongue: a video-illustrated case. BMJ case reports, 2013, Jul-08, Volume: 2013 Topics: Acute Disease; Angioedema; Dopamine Antagonists; Dystonia; Female; Humans; Metoclopramide; Middle Ag	2013
Chest pain a manifestation of migraine. The Journal of emergency medicine, 2014, Volume: 46, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Analgesics, Opioid; Chest Pain; Dopamine Antagonists; Electrocardiog	2014
Sustained hypotension following intravenous metoclopramide. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:11 Topics: Dopamine Antagonists; Female; Humans; Hypotension; Metoclopramide; Middle Aged; Migraine Disorders;	2013
Chlorpromazine for the treatment of migraine in a pediatric emergency department. Headache, 2014, Volume: 54, Issue:2 Topics: Adolescent; Child; Chlorpromazine; Cohort Studies; Dopamine Antagonists; Emergency Service, Hospital	2014
PURLs: treating migraine: the case for aspirin. The Journal of family practice, 2014, Volume: 63, Issue:2 Topics: Adolescent; Adult; Aged; Aspirin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, C	2014
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology, 2014, Oct-07, Volume: 83, Issue:15 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Female; Humans; Ketorolac; M	2014
Author response. Neurology, 2014, Oct-07, Volume: 83, Issue:15 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Female; Humans; Ketorolac; M	2014
Author response. Neurology, 2014, Oct-07, Volume: 83, Issue:15 Topics: Authorship; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Valproic Acid	2014
A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics, 2015, Volume: 135, Issue:2 Topics: Adolescent; Analgesics; Analgesics, Opioid; Child; Comparative Effectiveness Research; Diphenhydrami	2015
Intravenous migraine therapy in children with posttraumatic headache in the ED. The American journal of emergency medicine, 2015, Volume: 33, Issue:5 Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Brain Injuries;	2015
The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting. Pediatric emergency care, 2016, Volume: 32, Issue:7 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dihydroergotamine; Diphenhydramine	2016
Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache, 2016, Volume: 56, Issue:1 Topics: Adult; Dihydroergotamine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Expert Testimony; Fem	2016
Relative Effectiveness of Dopamine Antagonists for Pediatric Migraine in the Emergency Department. Pediatric emergency care, 2018, Volume: 34, Issue:3 Topics: Adolescent; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Child; Cohort Studies; Dopa	2018
An avoidable adverse drug reaction: Nicolau syndrome. International wound journal, 2017, Volume: 14, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dopamine D2 Receptor Antagonists; Female	2017
Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women. European journal of clinical pharmacology, 2016, Volume: 72, Issue:12 Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Breast Feeding; Cross-Sectio	2016
A 32-year-old woman with headache. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2016, Dec-06, Volume: 188, Issue:17-18 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Female; Humans; Metoclopramide; Migrain	2016
Comment on a Randomized Controlled Trial of Intravenous Haloperidol versus Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department. The Journal of emergency medicine, 2017, Volume: 52, Issue:3 Topics: Emergency Service, Hospital; Haloperidol; Humans; Metoclopramide; Migraine Disorders	2017
Metoclopramide inhibits trigeminovascular activation:evidence for effective acute attack treatment in migraine. Turkish journal of medical sciences, 2017, Feb-27, Volume: 47, Issue:1 Topics: Animals; Brain Chemistry; Cortical Spreading Depression; Disease Models, Animal; Male; Metoclopramid	2017
Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile. Cephalalgia : an international journal of headache, 2009, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Drug Combinations; Ergotamine; Female; Hu	2009
Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2010, Volume: 17, Issue:1 Topics: Antiemetics; Benzamides; Clinical Trials as Topic; Diphenhydramine; Dopamine Antagonists; Drug Combi	2010
Metoclopramide for migraines; how to stock a first aid kit. JAAPA : official journal of the American Academy of Physician Assistants, 2010, Volume: 23, Issue:11 Topics: Antiemetics; Emergency Service, Hospital; First Aid; Humans; Metoclopramide; Migraine Disorders; Off	2010
Capillary electrophoretic determination of antimigraine formulations containing caffeine, ergotamine, paracetamol and domperidone or metoclopramide. Journal of chromatographic science, 2013, Volume: 51, Issue:6 Topics: Acetaminophen; Caffeine; Domperidone; Drug Combinations; Drug Stability; Electrophoresis, Capillary;	2013
Strategies in the treatment of migraine. Mayo Clinic proceedings, 2002, Volume: 77, Issue:8 Topics: Analgesics; Antiemetics; Aspirin; Complementary Therapies; Humans; Lysine; Metoclopramide; Migraine	2002
Treatment of migraine. The New England journal of medicine, 2002, Sep-05, Volume: 347, Issue:10 Topics: Analgesics; Aspirin; Humans; Lysine; Metoclopramide; Migraine Disorders; Riboflavin; Serotonin Recep	2002
[More than six billions Euro costs due to illness days. Migraine therapy counts]. MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Cost of Ill	2003
Metoclopramide and sumatriptan. Headache, 2004, Volume: 44, Issue:5 Topics: Dopamine Antagonists; Drug Interactions; Drug Therapy, Combination; Humans; Metoclopramide; Migraine	2004
Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Current pain and headache reports, 2005, Volume: 9, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antiemetics; Dihydroergotamine; Diphenhydramine;	2005
Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). European journal of pharmacology, 2005, Jan-31, Volume: 508, Issue:1-3 Topics: Animals; Antiemetics; Butanols; Capsaicin; Cyclooxygenase Inhibitors; Dihydroergotamine; Diphenhydra	2005
A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology, 2005, Oct-25, Volume: 65, Issue:8 Topics: Anesthetics, Local; Clinical Trials as Topic; Diphenhydramine; Dopamine Antagonists; Drug Administra	2005
A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology, 2005, Oct-25, Volume: 65, Issue:8 Topics: Anesthetics, Local; Clinical Trials as Topic; Diphenhydramine; Dopamine Antagonists; Dose-Response R	2005
Metoclopramide for migraine-associated hiccup. International journal of clinical practice, 2006, Volume: 60, Issue:5 Topics: Adult; Antiemetics; Dopamine Antagonists; Hiccup; Humans; Male; Metoclopramide; Migraine Disorders	2006
Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache. The journal of pain, 2008, Volume: 9, Issue:1 Topics: Adult; Age Distribution; Analgesics, Opioid; Cohort Studies; Dopamine Antagonists; Drug Therapy, Com	2008
Treatment of the acute migraine attack--current status. Cephalalgia : an international journal of headache, 1983, Volume: 3, Issue:1 Topics: Acetaminophen; Aspirin; Drug Therapy, Combination; Ergotamine; Ergotamines; Humans; Metoclopramide;	1983
Migraine. Current concepts of pathogenesis and treatment. Drugs, 1983, Volume: 26, Issue:4 Topics: Adult; Analgesics; Anti-Inflammatory Agents; Cluster Headache; Ergotamine; Female; Humans; Lithium;	1983
Drug management of adult vascular headaches (migraine and cluster headache): Part I--Treatment of the acute attack. Iowa medicine : journal of the Iowa Medical Society, 1984, Volume: 74, Issue:11 Topics: Cluster Headache; Dihydroergotamine; Ergotamine; Humans; Metoclopramide; Migraine Disorders; Vascula	1984
Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. British journal of clinical pharmacology, 1984, Volume: 17, Issue:1 Topics: Absorption; Administration, Oral; Adult; Digestive System; Double-Blind Method; Drug Therapy, Combin	1984
A plain man's guide to the management of migraine. British medical journal (Clinical research ed.), 1982, Apr-10, Volume: 284, Issue:6322 Topics: Acetaminophen; Aspirin; Ergotamine; Headache; Humans; Metoclopramide; Migraine Disorders; Sleep	1982
How I manage migraine. Australian family physician, 1981, Volume: 10, Issue:8 Topics: Aspirin; Ergotamine; Female; Humans; Metoclopramide; Migraine Disorders; Relaxation Therapy; Tranqui	1981
Aspirin treatment of migraine attacks: plasma drug level data. Cephalalgia : an international journal of headache, 1982, Volume: 2, Issue:1 Topics: Adolescent; Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle	1982
Migraine: a rational approach to therapy. The British journal of clinical practice, 1982, Volume: 36, Issue:10 Topics: Acetaminophen; Adolescent; Adult; Aged; Child; Drug Combinations; Female; Humans; Male; Metocloprami	1982
[Menstrual migraine]. Minerva medica, 1982, Mar-24, Volume: 73, Issue:12 Topics: Adult; Bromocriptine; Chiari-Frommel Syndrome; Estrogens; Female; Galactorrhea; Gout; Humans; Menstr	1982
A double blind study of metoclopramide in the treatment of migraine attacks. Journal of neurology, neurosurgery, and psychiatry, 1980, Volume: 43, Issue:4 Topics: Acetaminophen; Adolescent; Adult; Aged; Diazepam; Double-Blind Method; Drug Therapy, Combination; Fe	1980
Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. European neurology, 1980, Volume: 19, Issue:3 Topics: Acetaminophen; Acute Disease; Aspirin; Diazepam; Drug Evaluation; Drug Therapy, Combination; Humans;	1980
Study of migraine and the treatment of acute attacks in industry. The Journal of international medical research, 1980, Volume: 8, Issue:5 Topics: Absenteeism; Acetaminophen; Adolescent; Adult; England; Female; Humans; Male; Metoclopramide; Middle	1980
Metoclopramide/analgesic combinations for migraine. Drug and therapeutics bulletin, 1980, Nov-21, Volume: 18, Issue:24 Topics: Analgesics; Drug Combinations; Humans; Metoclopramide; Migraine Disorders	1980
Treatment of migraine headache after ocular surgery with intravenous metoclopramide hydrochloride. American journal of ophthalmology, 1996, Volume: 121, Issue:1 Topics: Adult; Cataract Extraction; Dopamine Antagonists; Female; Humans; Injections, Intravenous; Lenses, I	1996
Prochlorperazine or metoclopramide? Annals of emergency medicine, 1996, Volume: 27, Issue:4 Topics: Antiemetics; Humans; Metoclopramide; Migraine Disorders; Prochlorperazine; Research Design	1996
[Paracetamol and metoclopramide in fixed combination?]. Medizinische Monatsschrift fur Pharmazeuten, 1996, Volume: 19, Issue:4 Topics: Acetaminophen; Analgesics, Non-Narcotic; Antiemetics; Drug Combinations; Humans; Metoclopramide; Mig	1996
Bionursing: the management of migraine and vomiting. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 1996, Jan-31, Volume: 10, Issue:19 Topics: Aged; Antiemetics; Female; Humans; Methysergide; Metoclopramide; Migraine Disorders; Occupational He	1996
[Differentiated therapy of migraine attack]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1999, Volume: 99, Issue:12 Topics: Adult; Analgesics; Antiemetics; Aspirin; Combined Modality Therapy; Drug Therapy, Combination; Femal	1999
[Effect of migraine medications on monocyte chemotaxis] . Anaesthesiologie und Reanimation, 2000, Volume: 25, Issue:4 Topics: Adult; Analgesics; Aspirin; Chemotaxis, Leukocyte; Dihydroergotamine; Humans; Immune Tolerance; Male	2000
What is the optimal strategy for managing acute migraine headaches? The Journal of family practice, 2001, Volume: 50, Issue:2 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Disabled Persons; Drug	2001
The Copenhagen Acute Headache Clinic: organization, patient material and treatment results. Headache, 1979, Volume: 19, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Analgesics; Anti-Anxiety Agents; Biperiden; Denmark; Female;	1979
Anti-nauseant drugs. The Practitioner, 1979, Volume: 223, Issue:1336 Topics: Antiemetics; Antipsychotic Agents; Female; Gastrointestinal Diseases; Histamine H1 Antagonists; Huma	1979
[Experience with 750 migraine patients at a headache clinic]. Ugeskrift for laeger, 1979, Sep-03, Volume: 141, Issue:36 Topics: Acetaminophen; Adult; Aged; Aspirin; Diazepam; Drug Evaluation; Drug Therapy, Combination; Female; H	1979
Metoclopramide in migrane treatment. The Medical journal of Australia, 1977, Oct-22, Volume: 2, Issue:17 Topics: Humans; Metoclopramide; Migraine Disorders	1977
Observations on the treatment of an acute attack of migraine. Research and clinical studies in headache, 1978, Volume: 6 Topics: Acute Disease; Analgesics; Diazepam; Ergotamine; Female; Headache; Humans; Hypnotics and Sedatives;	1978
[Metoclopramide (Primperan) in migraine]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1978, Oct-30, Volume: 98, Issue:30 Topics: Drug Evaluation; Humans; Metoclopramide; Migraine Disorders	1978
Ergotamine-metoclopramide for migraine: is it enough? Headache, 1992, Volume: 32, Issue:9 Topics: Drug Combinations; Ergotamine; Humans; Metoclopramide; Migraine Disorders	1992
Abortive migraine therapy with oral naproxen sodium plus metoclopramide plus ergotamine tartrate with caffeine. Headache, 1992, Volume: 32, Issue:2 Topics: Adult; Caffeine; Drug Combinations; Ergotamine; Humans; Metoclopramide; Middle Aged; Migraine Disord	1992
[Pharmacokinetic aspects of a combination of metoclopramide and paracetamol. Results of a human kinetic study and consequences for migraine patients]. Arzneimittel-Forschung, 1992, Volume: 42, Issue:4 Topics: Acetaminophen; Adult; Biological Availability; Drug Combinations; Female; Half-Life; Humans; Male; M	1992
Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache, 1991, Volume: 31, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Drug Therapy, Combination; Humans; Ketor	1991
The use of metoclopramide for control of migraine cephalgia. Annals of emergency medicine, 1991, Volume: 20, Issue:6 Topics: Data Interpretation, Statistical; Humans; Metoclopramide; Migraine Disorders; Research Design	1991
Intravenous lignocaine for migraine headache. Australian family physician, 1989, Volume: 18, Issue:12 Topics: Aspirin; Humans; Injections, Intravenous; Lidocaine; Metoclopramide; Migraine Disorders	1989
Migraine--treatment of acute attack. Scottish medical journal, 1985, Volume: 30, Issue:4 Topics: Acetaminophen; Acute Disease; Aspirin; Caffeine; Ergotamine; Ergotamines; Humans; Metoclopramide; Mi	1985
Management of the migraine patient. American family physician, 1986, Volume: 33, Issue:1 Topics: Amitriptyline; Analgesics; Diagnosis, Differential; Diet; Ergotamine; Humans; Hypnotics and Sedative	1986
[Value of oral primperan in the treatment of migraine]. Annales de gastroenterologie et d'hepatologie, 1985, May-28, Volume: 21, Issue:2 Pt 2 Topics: Aspirin; Gastric Emptying; Humans; Metoclopramide; Migraine Disorders	1985
Adverse reactions to drugs in migraine: some recent reports. Human toxicology, 1985, Volume: 4, Issue:5 Topics: Domperidone; Ergotamine; Humans; Metoclopramide; Migraine Disorders	1985

metoclopramide and Migraine Disorders